CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.690
-0.510 (-15.94%)
Sep 15, 2026, 4:00 PM EDT - Market closed
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $1.42M in the quarter ending June 30, 2026, a decrease of -92.40%. This brings the company's revenue in the last twelve months to $18.30M, down -87.03% year-over-year. In the year 2025, CytomX Therapeutics had annual revenue of $76.20M, down -44.82%.
Revenue (ttm)
$18.30M
Revenue Growth
-87.03%
P/S Ratio
32.02
Revenue / Employee
$265,261
Employees
69
Market Cap
586.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76.20M | -61.90M | -44.82% |
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Valneva SE | 163.30M |
| Scribe Therapeutics | 33.30M |
| Allogene Therapeutics | 4.64M |
| Prime Medicine | 4.07M |
| Oculis Holding AG | 1.45M |
| Shattuck Labs | 1.00M |
| Altimmune | 31.00K |
CTMX News
- 1 day ago - CytomX Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 days ago - CytomX Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 days ago - CytomX Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 7 days ago - CytomX Therapeutics Slides: Wells Fargo 21st Annual Healthcare Conference - Filings
- 14 days ago - CytomX Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewsWire
- 19 days ago - CytomX Therapeutics gets Fast Track Designation for Varseta-M - TheFly
- 19 days ago - CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - GlobeNewsWire
- 4 weeks ago - CytomX Therapeutics price target lowered to $11 from $12 at JPMorgan - TheFly